{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:49:36Z","timestamp":1794005376539,"version":"4.8.0"},"reference-count":309,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ejmech.2021.113865","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T11:08:01Z","timestamp":1632395281000},"page":"113865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Recent contributions of quinolines to antimalarial and anticancer drug discovery research"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1427-2790","authenticated-orcid":false,"given":"Tim","family":"Van de Walle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0583-5042","authenticated-orcid":false,"given":"Lore","family":"Cools","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9349-880X","authenticated-orcid":false,"given":"Sven","family":"Mangelinckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"D'hooghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113865_bib1","doi-asserted-by":"crossref","first-page":"111353","DOI":"10.1016\/j.ejmech.2019.05.043","article-title":"New dimensions in the field of antimalarial research against malaria resurgence","volume":"181","author":"Narula","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib2","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1016\/j.bmc.2014.12.018","article-title":"Quinoline-based antimalarial hybrid compounds","volume":"23","author":"Vandekerckhove","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/17460441.2017.1319357","article-title":"An overview of quinoline as a privileged scaffold in cancer drug discovery","volume":"12","author":"Musiol","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.113865_bib4","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.2174\/092986710791163966","article-title":"Quinoline-based antifungals","volume":"17","author":"Musiol","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/med.21262","article-title":"Antituberculosis drug research: a critical overview","volume":"33","author":"Beena","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2021.113865_bib6","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.2174\/1385272821666170207103634","article-title":"Quinoline alkaloids against neglected tropical diseases","volume":"21","author":"Musiol","year":"2017","journal-title":"Curr. Org. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11030-019-09953-4","article-title":"Insights into the current status of privileged N-heterocycles as antileishmanial agents","volume":"24","author":"Razzaghi-Asl","year":"2020","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2021.113865_bib8","doi-asserted-by":"crossref","first-page":"782","DOI":"10.22270\/jddt.v9i4-s.3414","article-title":"Quinoline as TRPV1 antagonists: a new approach against inflammation","volume":"9","author":"Ambatkar","year":"2019","journal-title":"J.\u00a0Drug Deliv. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113865_bib9","first-page":"389","article-title":"Quinolines: a new hope against inflammation, Drug Discov","volume":"18","author":"Mukherjee","year":"2013","journal-title":"Today Off."},{"key":"10.1016\/j.ejmech.2021.113865_bib10a","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2174\/1389557518666181018163448","article-title":"A\u00a0review on quinoline derived scaffolds as anti-HIV agents","volume":"19","author":"Chokkar","year":"2019","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib10b","doi-asserted-by":"crossref","first-page":"113220","DOI":"10.1016\/j.ejmech.2021.113220","article-title":"Synthetic and medicinal perspective of quinolines as antiviral agents","volume":"215","author":"Kaur","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib11","series-title":"World Malaria Report 2020. Geneva","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.ejmech.2021.113865_bib12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(13)60024-0","volume":"383","author":"White","year":"2014","journal-title":"Malaria, Lancet"},{"key":"10.1016\/j.ejmech.2021.113865_bib13","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1016\/j.ejmech.2009.02.024","article-title":"Recent developments in the design and synthesis of hybrid molecules based on aminoquinoline ring and their antiplasmodial evaluation","volume":"44","author":"Kouznetsov","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib14","series-title":"Burger's Med. Chem. Drug Discov.","article-title":"Antimalarials","author":"Smithson","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113865_bib15","series-title":"Adv. Malar. Res.","first-page":"383","article-title":"Antimalarial drug resistance","author":"Shah","year":"2016"},{"key":"10.1016\/j.ejmech.2021.113865_bib16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1098\/rspb.2002.2241","article-title":"The de novo selection of drug-resistant malaria parasites","volume":"270","author":"White","year":"2003","journal-title":"Proc. R. Soc. B Biol. Sci."},{"key":"10.1016\/j.ejmech.2021.113865_bib17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.pt.2016.05.010","article-title":"Artemisinin action and resistance in Plasmodium falciparum","volume":"32","author":"Tilley","year":"2016","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ejmech.2021.113865_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2021.113865_bib19","author":"WHO"},{"key":"10.1016\/j.ejmech.2021.113865_bib20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","article-title":"Cancer metastasis: building a framework","volume":"127","author":"Gupta","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2021.113865_bib22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib23","first-page":"7","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2021.113865_bib24","doi-asserted-by":"crossref","first-page":"20784","DOI":"10.1039\/D0RA03763J","article-title":"Recent advances in the synthesis of biologically and pharmaceutically active quinoline and its analogues: a review","volume":"10","author":"Weyesa","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2021.113865_bib25","first-page":"1","article-title":"Recent advances on diversity oriented heterocycle synthesis of fused quinolines and its biological evaluation","author":"Abass","year":"2020","journal-title":"Polycycl. Aromat. Comp."},{"key":"10.1016\/j.ejmech.2021.113865_bib26","doi-asserted-by":"crossref","first-page":"19867","DOI":"10.1039\/D0RA02786C","article-title":"Advancements in the synthesis of fused tetracyclic quinoline derivatives","volume":"10","author":"Mekheimer","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2021.113865_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejmech.2018.10.035","article-title":"Quinoline and quinolone dimers and their biological activities: an overview","volume":"161","author":"Chu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib28","first-page":"1","article-title":"Structural and biological survey of 7-chloro-4-(piperazin-1-yl)quinoline and its derivatives","author":"El-Azzouny","year":"2020","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib29","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1016\/j.bmc.2014.12.018","article-title":"Quinoline-based antimalarial hybrid compounds","volume":"23","author":"Vandekerckhove","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejmech.2014.11.022","article-title":"Shahjahan, Reemergence of chloroquine (CQ) analogs as multi-targeting antimalarial agents: a review","volume":"90","author":"Mushtaque","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib31","doi-asserted-by":"crossref","first-page":"11865","DOI":"10.1073\/pnas.93.21.11865","article-title":"On the molecular mechanism of chloroquine's antimalarial action","volume":"93","author":"Sullivan","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2021.113865_bib32","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jinorgbio.2007.12.004","article-title":"Recent advances in understanding the mechanism of hemozoin (malaria pigment) formation","volume":"102","author":"Egan","year":"2008","journal-title":"J.\u00a0Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2021.113865_bib33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1126\/science.1074045","article-title":"Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations","volume":"298","author":"Singh Sidhu","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.113865_bib34","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/35002615","article-title":"Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum","volume":"403","author":"Reed","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113865_bib35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.actatropica.2005.04.008","article-title":"Contribution of the pfmdr1 gene to antimalarial drug-resistance","volume":"94","author":"Duraisingh","year":"2005","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejmech.2021.113865_bib36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/ddr.20345","article-title":"Next-generation antimalarial drugs: hybrid molecules as a new strategy in drug design","volume":"71","author":"Muregi","year":"2010","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib37","doi-asserted-by":"crossref","first-page":"11164","DOI":"10.1021\/cr500123g","article-title":"\u201cRecycling\u201d classical drugs for malaria","volume":"114","author":"Teixeira","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2021.113865_bib38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bcp.2011.04.018","article-title":"Effects of highly active novel artemisinin-chloroquinoline hybrid compounds on \u03b2-hematin formation, parasite morphology and endocytosis in Plasmodium falciparum","volume":"82","author":"Feng","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113865_bib39","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1016\/j.bmcl.2007.04.054","article-title":"A\u00a0novel artemisinin-quinine hybrid with potent antimalarial activity","volume":"17","author":"Walsh","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib40","doi-asserted-by":"crossref","first-page":"13066","DOI":"10.1002\/anie.201907224","article-title":"Artemisinin\u2013(Iso)quinoline hybrids by C\u2212H activation and click chemistry: combating multidrug-resistant malaria","volume":"58","author":"\u00c7apc\u0131","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2021.113865_bib41","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/cmdc.201800728","article-title":"Targeting asexual and sexual blood stages of the human malaria parasite P. Falciparum with 7-chloroquinoline-based 1,2,3-triazoles","volume":"14","author":"Wadi","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113865_bib42","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.3390\/molecules24122310","article-title":"Antiplasmodial activity and in\u00a0vivo bio-distribution of chloroquine molecules released with a 4-(4-ethynylphenyl)-triazole moiety from organometallo-cobalamins","volume":"24","author":"Rossier","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.113865_bib43","doi-asserted-by":"crossref","first-page":"13200","DOI":"10.1021\/acsomega.8b01833","article-title":"Synthesis and evaluation of antiplasmodial efficacy of \u03b2-carboline derivatives against murine malaria","volume":"3","author":"Gorki","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2021.113865_bib44","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1126\/science.1193225","article-title":"Spiroindolones, a potent compound class for the treatment of malaria","volume":"329","author":"Rottmann","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.113865_bib45","doi-asserted-by":"crossref","first-page":"126810","DOI":"10.1016\/j.bmcl.2019.126810","article-title":"Synthesis, anti-plasmodial and cytotoxic evaluation of 1H-1,2,3-triazole\/acyl hydrazide integrated tetrahydro-\u03b2-carboline-4-aminoquinoline conjugates","volume":"30","author":"Sharma","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib46","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1021\/acs.cgd.8b01049","article-title":"Investigation into the structures and properties of multicomponent crystals formed from a series of 7-chloroquinolines and aromatic acids","volume":"19","author":"Clements","year":"2019","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejmech.2021.113865_bib47","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1021\/jm701247k","article-title":"Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies","volume":"51","author":"Gemma","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib48","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bioorg.2018.06.012","article-title":"Design, synthesis and antiplasmodial activity of novel imidazole derivatives based on 7-chloro-4-aminoquinoline","volume":"80","author":"Kondaparla","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib49","doi-asserted-by":"crossref","first-page":"16823","DOI":"10.1073\/pnas.1204556109","article-title":"Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target","volume":"109","author":"Yuthavong","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2021.113865_bib50","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ejmech.2014.10.061","article-title":"4-Aminoquinoline-Pyrimidine hybrids: synthesis, antimalarial activity, heme binding and docking studies","volume":"89","author":"Kumar","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejmech.2017.07.061","article-title":"Quinoline hybrids and their antiplasmodial and antimalarial activities","volume":"139","author":"Hu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejmech.2018.02.021","article-title":"Pyrimidine-chloroquinoline hybrids: synthesis and antiplasmodial activity","volume":"148","author":"Chopra","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib53","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejmech.2018.11.021","article-title":"N-Substituted aminoquinoline-pyrimidine hybrids: synthesis, in\u00a0vitro antimalarial activity evaluation and docking studies","volume":"162","author":"Maurya","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib54","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1021\/acsmedchemlett.8b00222","article-title":"Potent antimalarial activity of two arenes linked with triamine designed to have multiple interactions with heme","volume":"9","author":"Sakata","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113865_bib55","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejmech.2017.11.033","article-title":"Microwave-promoted facile access to 4-aminoquinoline-phthalimides: synthesis and anti-plasmodial evaluation","volume":"143","author":"Rani","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib56","doi-asserted-by":"crossref","first-page":"102912","DOI":"10.1016\/j.bioorg.2019.04.006","article-title":"Substituted 1,3-dioxoisoindoline-4-aminoquinolines coupled via amide linkers: synthesis, antiplasmodial and cytotoxic evaluation","volume":"88","author":"Rani","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4155\/fmc-2019-0260","article-title":"Design, synthesis, heme binding and density functional theory studies of isoindoline-dione-4-aminoquinolines as potential antiplasmodials","volume":"12","author":"Rani","year":"2020","journal-title":"Futur. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib58","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1021\/acsmedchemlett.9b00521","article-title":"Functionalized naphthalimide-4-aminoquinoline conjugates as promising antiplasmodials, with mechanistic insights","volume":"11","author":"Shalini","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113865_bib59","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/cbdd.12914","article-title":"Design, synthesis and in\u00a0vitro antiplasmodial activity of some bisquinolines against chloroquine-resistant strain","volume":"89","author":"Kondaparla","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2021.113865_bib60","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1021\/jm020960r","article-title":"Synthesis and in\u00a0vitro and in\u00a0vivo antimalarial activity of N1-(7-chloro-4-quinolyl)-1,4-bis(3-aminopropyl)piperazine derivatives","volume":"46","author":"Ryckebusch","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib61","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0960-894X(01)00383-3","article-title":"Synthesis, antimalarial activity and inhibition of haem detoxification of novel bisquinolines","volume":"11","author":"Ayad","year":"2001","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib62","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.3390\/molecules25092251","article-title":"Unsymmetrical bisquinolines with high potency against P. Falciparum malaria","volume":"25","author":"Liebman","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.113865_bib63","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s00044-013-0748-4","article-title":"Synthesis, in\u00a0vitro antiplasmodial and antiproliferative activities of a series of quinoline-ferrocene hybrids","volume":"23","author":"N\u2019Da","year":"2014","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejmech.2019.06.069","article-title":"Bioisosteric ferrocenyl aminoquinoline-benzimidazole hybrids: antimicrobial evaluation and mechanistic insights","volume":"180","author":"Baartzes","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib65","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejmech.2018.08.063","article-title":"Novel antimalarial chloroquine- and primaquine-quinoxaline 1,4-di-N-oxide hybrids: design, synthesis, Plasmodium life cycle stage profile, and preliminary toxicity studies","volume":"158","author":"Bonilla-Ramirez","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib66","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1007\/s00044-019-02435-0","article-title":"Antimalarial, antiproliferative, and apoptotic activity of quinoline-chalcone and quinoline-pyrazoline hybrids. A dual action","volume":"28","author":"Charris","year":"2019","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib67","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.drup.2006.09.002","article-title":"Quinoline-resistance reversing agents for the malaria parasite Plasmodium falciparum","volume":"9","author":"van Schalkwyk","year":"2006","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2021.113865_bib68","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1016\/j.bmcl.2014.09.088","article-title":"Pentacycloundecylamines and conjugates thereof as chemosensitizers and reversed chloroquine agents","volume":"24","author":"Joubert","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib69","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.bmcl.2016.01.052","article-title":"Polycyclic amines as chloroquine resistance modulating agents in Plasmodium falciparum","volume":"26","author":"Joubert","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib70","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.bmcl.2018.03.026","article-title":"Adamantane amine-linked chloroquinoline derivatives as chloroquine resistance modulating agents in Plasmodium falciparum","volume":"28","author":"Yvette","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib71","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1007\/s00436-018-6057-6","article-title":"In\u00a0vivo and in\u00a0vitro antimalarial effect and toxicological evaluation of the chloroquine analogue PQUI08001\/06","volume":"117","author":"Reis","year":"2018","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib72","first-page":"161","article-title":"Synthesis and antimalarial activity of (S)-methyl-(7-chloroquinolin-4-ylthio)acetamidoalquilate derivatives","volume":"44","author":"Colmenarez","year":"2020","journal-title":"J\u00a0Chem. Res. (Synop.)"},{"key":"10.1016\/j.ejmech.2021.113865_bib73","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1007\/s10637-011-9716-3","article-title":"Effect of quinolinyl acrylate derivatives on prostate cancer in\u00a0vitro and in\u00a0vivo","volume":"30","author":"Rodrigues","year":"2012","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2021.113865_bib74","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.bmc.2017.12.022","article-title":"Optimization of antimalarial, and anticancer activities of (E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl) acrylate","volume":"26","author":"Romero","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib75","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0140-6736(86)92371-8","article-title":"Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria","volume":"327","author":"Hatton","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2021.113865_bib76","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0022-3565(25)09582-5","article-title":"The effect of chemical substitution on the metabolic activation, metabolic detoxication, and pharmacological activity of amodiaquine in the mouse","volume":"273","author":"Ruscoe","year":"1995","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113865_bib77","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1021\/jm00035a017","article-title":"The effect of fluorine substitution on the metabolism and antimalarial activity of amodiaquine","volume":"37","author":"O\u2032Neill","year":"1994","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib78","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1021\/acsmedchemlett.8b00496","article-title":"Hybridization of fluoro-amodiaquine (FAQ) with pyrimidines: synthesis and antimalarial efficacy of FAQ-pyrimidines","volume":"10","author":"Tripathi","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113865_bib79","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/jac\/dks471","article-title":"Antimalarial activity of isoquine against Kenyan Plasmodium falciparum clinical isolates and association with polymorphisms in pfcrt and pfmdr1 genes","volume":"68","author":"Okombo","year":"2013","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2021.113865_bib80","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ejmech.2017.10.051","article-title":"Synthesis, \u03b2-hematin inhibition studies and antimalarial evaluation of new dehydroxy isoquine derivatives against Plasmodium berghei: a promising antimalarial agent","volume":"148","author":"Valverde","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib81","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.tetlet.2019.05.054","article-title":"Microwave-assisted, rapid synthesis of 2-vinylquinolines and evaluation of their antimalarial activity","volume":"60","author":"Huang","year":"2019","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2021.113865_bib82","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejmech.2017.04.022","article-title":"Guanylthiourea derivatives as potential antimalarial agents: synthesis, in\u00a0vivo and molecular modelling studies","volume":"135","author":"Bhagat","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib83","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bmcl.2013.12.009","article-title":"Design and synthesis of guanylthiourea derivatives as potential inhibitors of Plasmodium falciparum dihydrofolate reductase enzyme","volume":"24","author":"Adane","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib84","doi-asserted-by":"crossref","first-page":"103094","DOI":"10.1016\/j.bioorg.2019.103094","article-title":"Design, synthesis and biological evaluation of 4-aminoquinoline-guanylthiourea derivatives as antimalarial agents","volume":"91","author":"Bhagat","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib85","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/acs.jmedchem.5b00515","article-title":"Protozoan parasite growth inhibitors discovered by cross-screening yield potent scaffolds for lead discovery","volume":"58","author":"Devine","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib86","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.113865_bib87","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1021\/acsinfecdis.7b00212","article-title":"Optimization of physicochemical properties for 4-anilinoquinoline inhibitors of Plasmodium falciparum proliferation","volume":"4","author":"Mehta","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2021.113865_bib88","doi-asserted-by":"crossref","first-page":"10737","DOI":"10.1002\/anie.201804551","article-title":"C\u2212H activation enables a concise total synthesis of quinine and analogues with enhanced antimalarial activity","volume":"57","author":"O\u2019\u00a0Donovan","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2021.113865_bib89","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1128\/AAC.42.11.2973","article-title":"Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols","volume":"42","author":"Mungthin","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113865_bib90","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2478\/acph-2019-0019","article-title":"Synthesis and antiplasmodial evaluation of novel mefloquine-based fumardiamides","volume":"69","author":"Beus","year":"2019","journal-title":"Acta Pharm."},{"key":"10.1016\/j.ejmech.2021.113865_bib91","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.bmc.2019.01.044","article-title":"New hybrid trifluoromethylquinolines as antiplasmodium agents","volume":"27","author":"da Silva","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib92","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/ph12030115","article-title":"Novel FDA-approved prodrug for the radical cure of Plasmodium vivax malaria and prophylaxis of malaria","volume":"12","author":"Mayence","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2021.113865_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0006230","article-title":"Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries","volume":"12","author":"Recht","year":"2018","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2021.113865_bib94","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1179\/000349804225003550","article-title":"A\u00a0prospective study evaluating the efficacy of a single, 45-mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India","volume":"98","author":"Kamtekar","year":"2004","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"10.1016\/j.ejmech.2021.113865_bib95","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1021\/ml4002985","article-title":"Novel endoperoxide-based transmission-blocking antimalarials with liver- and blood-schizontocidal activities","volume":"5","author":"Miranda","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113865_bib96","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ejmech.2008.08.011","article-title":"Primaquine revisited six decades after its discovery","volume":"44","author":"Vale","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib97","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejmech.2018.02.048","article-title":"Endoperoxide-8-aminoquinoline hybrids as dual-stage antimalarial agents with enhanced metabolic stability","volume":"149","author":"Capela","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib98","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4269\/ajtmh.1992.46.169","article-title":"Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR mice and Anopheles stephensi mosquitoes","volume":"46","author":"Coleman","year":"1992","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2021.113865_bib99","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/AAC.00777-06","article-title":"In\u00a0vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti, Antimicrob","volume":"50","author":"Pradines","year":"2006","journal-title":"Agents Chemother"},{"key":"10.1016\/j.ejmech.2021.113865_bib100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13318-013-0139-8","article-title":"An LC-MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in\u00a0vitro primary human hepatocyte culture model","volume":"39","author":"Jin","year":"2014","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2021.113865_bib101","first-page":"408","article-title":"Identification of inhibitors of Plasmodium falciparum gametocyte development, Malar","volume":"12","author":"Duffy","year":"2013","journal-title":"J"},{"key":"10.1016\/j.ejmech.2021.113865_bib102","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/cmdc.201800691","article-title":"8-Aminoquinolines with an aminoxyalkyl side chain exert in\u00a0vitro dual-stage antiplasmodial activity","volume":"14","author":"Leven","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113865_bib103","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1021\/acsomega.7b02047","article-title":"Synthesis and biological evaluation of 8-quinolinamines and their amino acid conjugates as broad-spectrum anti-infectives","volume":"3","author":"Jain","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2021.113865_bib104","doi-asserted-by":"crossref","first-page":"126614","DOI":"10.1016\/j.bmcl.2019.08.018","article-title":"Primaquine homodimers as potential antiplasmodial and anticancer agents","volume":"29","author":"Pavi\u0107","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s42250-019-00096-5","article-title":"Development of antimicrobial, antimalarial and antitubercular compounds based on a quinoline-pyrazole clubbed scaffold derived via doebner reaction","volume":"3","author":"Pandya","year":"2020","journal-title":"Chem. Africa."},{"key":"10.1016\/j.ejmech.2021.113865_bib106","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jhet.3080","article-title":"Synthesis, docking, ADME-tox study of 2-(2-(2-Chlorophenyl)quinoline-4-carbonyl)-N-substituted hydrazinecarbothioamide derivatives and their biological evaluation","volume":"55","author":"Patel","year":"2018","journal-title":"J.\u00a0Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib107","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/jhet.3617","article-title":"Design, synthesis, and biological and in silico study of fluorine-containing quinoline hybrid thiosemicarbazide analogues","volume":"56","author":"Patel","year":"2019","journal-title":"J.\u00a0Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib108","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/jhet.3855","article-title":"Synthesis of novel quinoline-thiosemicarbazide hybrids and evaluation of their biological activities, molecular docking, molecular dynamics, pharmacophore model studies, and ADME-Tox properties","volume":"57","author":"Patel","year":"2020","journal-title":"J.\u00a0Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib109","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/jhet.3848","article-title":"A\u00a0green synthesis of quinoline-4-carboxylic derivatives using p-toluenesulfonic acid as an efficient organocatalyst under microwave irradiation and their docking, molecular dynamics, ADME-Tox and biological evaluation","volume":"57","author":"Patel","year":"2020","journal-title":"J.\u00a0Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib110","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00018-011-0906-0","article-title":"Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics, Cell","volume":"69","author":"Summers","year":"2012","journal-title":"Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2021.113865_bib111","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1021\/jm990437l","article-title":"Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of \u03b2- hematin formation, and antiplasmodial activity","volume":"43","author":"Egan","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2161-0444.1000315","article-title":"4-aminoquinolines: an overview of antimalarial chemotherapy","volume":"6","author":"Deshpande","year":"2016","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib113","doi-asserted-by":"crossref","first-page":"112330","DOI":"10.1016\/j.ejmech.2020.112330","article-title":"Synthesis and biological evaluation of novel quinoline-piperidine scaffolds as antiplasmodium agents","volume":"198","author":"Van de Walle","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib114","doi-asserted-by":"crossref","first-page":"111963","DOI":"10.1016\/j.ejmech.2019.111963","article-title":"Design and synthesis of novel ferrocene-quinoline conjugates and evaluation of their electrochemical and antiplasmodium properties","volume":"187","author":"Mini\u0107","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib115","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.bmc.2017.02.043","article-title":"New derivatives of quinoline-4-carboxylic acid with antiplasmodial activity","volume":"25","author":"Hochegger","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib116","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","article-title":"A\u00a0novel multiple-stage antimalarial agent that inhibits protein synthesis","volume":"522","author":"Baraga\u00f1a","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113865_bib117","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.bmc.2019.03.061","article-title":"Synthesis and structure-activity relationships for new 6-fluoroquinoline derivatives with antiplasmodial activity","volume":"27","author":"Hochegger","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib118","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.exppara.2018.01.015","article-title":"Novel arylidene derivatives of quinoline based thiazolidinones: synthesis, in\u00a0vitro, in\u00a0vivo and in silico study as antimalarials","volume":"185","author":"Jain","year":"2018","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ejmech.2021.113865_bib119","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10822-019-00210-2","article-title":"Anti-malarial, cytotoxicity and molecular docking studies of quinolinyl chalcones as potential anti-malarial agent","volume":"33","author":"Hameed","year":"2019","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2021.113865_bib120","doi-asserted-by":"crossref","first-page":"959","DOI":"10.14233\/ajchem.2020.22542","article-title":"Synthesis and biological evaluation of some novel quinoline based chalcones as potent antimalarial, anti-inflammatory, antioxidant and antidiabetic agents","volume":"4","author":"Peerzade","year":"2020","journal-title":"Asian J. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib121","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/cbdd.13164","article-title":"Design, synthesis, and antiprotozoal evaluation of new 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline derivatives","volume":"91","author":"Guillon","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2021.113865_bib122","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/14756366.2019.1706502","article-title":"Design, synthesis, and antiprotozoal evaluation of new 2,4-bis[(substituted-aminomethyl)phenyl]quinoline, 1,3-bis[(substituted-aminomethyl)phenyl]isoquinoline and 2,4-bis[(substituted-aminomethyl)phenyl]quinazoline derivatives","volume":"35","author":"Guillon","year":"2020","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib123","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1590\/0001-3765201820170820","article-title":"2,3,8-trisubstituted quinolines with antimalarial activity","volume":"90","author":"Martinez","year":"2018","journal-title":"An. Acad. Bras. Cienc."},{"key":"10.1016\/j.ejmech.2021.113865_bib124","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.mpmed.2011.09.012","article-title":"Cytotoxic chemotherapy: clinical aspects","volume":"39","author":"Corrie","year":"2011","journal-title":"Medicine"},{"key":"10.1016\/j.ejmech.2021.113865_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/aps.2015.93","article-title":"Precision cancer medicine: where to target?","volume":"36","author":"Yu","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2021.113865_bib126","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.113865_bib127","first-page":"79","article-title":"Protein kinases as targets for anticancer agents: from inhibitors to useful drugs, Pharmacol","volume":"93","author":"Fabbro","year":"2002","journal-title":"Therapy"},{"key":"10.1016\/j.ejmech.2021.113865_bib128","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clinbiochem.2004.05.006","article-title":"Tyrosine kinase inhibitors in cancer therapy","volume":"37","author":"Madhusudan","year":"2004","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejmech.2021.113865_bib129","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.28864","article-title":"The MAPK pathway across different malignancies: a new perspective","volume":"120","author":"Burotto","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2021.113865_bib130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/14756366.2017.1407926","article-title":"Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study","volume":"33","author":"El-Sayed","year":"2018","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib131","first-page":"186","article-title":"Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors, Bioorg","volume":"83","author":"George","year":"2019","journal-title":"Inside Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib132","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.bmcl.2019.04.029","article-title":"Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors","volume":"29","author":"Mansour","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib133","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.prp.2015.04.003","article-title":"Expression and prognostic significance of VEGFR-2 in breast cancer","volume":"211","author":"Yan","year":"2015","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ejmech.2021.113865_bib134","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0006-2952(00)00529-3","article-title":"Angiogenesis: regulators and clinical applications","volume":"61","author":"Liekens","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113865_bib135","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0140-6736(94)92692-1","article-title":"Risk of endometrial cancer after tamoxifen treatment of breast cancer","volume":"343","author":"van Leeuwen","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2021.113865_bib136","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrc2713","article-title":"Biological determinants of endocrine resistance in breast cancer","volume":"9","author":"Musgrove","year":"2009","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2021.113865_bib137","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.ejca.2010.02.018","article-title":"Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2\/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors","volume":"46","author":"Patel","year":"2010","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.ejmech.2021.113865_bib138","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejmech.2018.10.045","article-title":"Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ER\u03b1 and VEGFR-2","volume":"161","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib139","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrm3012","article-title":"MET signalling: principles and functions in development, organ regeneration and cancer","volume":"11","author":"Trusolino","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.113865_bib140","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2021.113865_bib141","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.molmed.2005.04.005","article-title":"Cancer therapy: can the challenge be MET?","volume":"11","author":"Corso","year":"2005","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2021.113865_bib142","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/0008-5472.CAN-05-2749","article-title":"Somatic mutations lead to an oncogenic deletion of Met in lung cancer","volume":"66","author":"Kong-Beltran","year":"2006","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib143","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.bmc.2013.04.013","article-title":"Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors","volume":"21","author":"Li","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib144","doi-asserted-by":"crossref","first-page":"1900101","DOI":"10.1002\/ardp.201900101","article-title":"Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors","volume":"352","author":"Lien","year":"2019","journal-title":"Arch. Der Pharm. Chem. Life Sci."},{"key":"10.1016\/j.ejmech.2021.113865_bib145","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.bmcl.2016.02.037","article-title":"Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 2-oxo-4-chloro-1,2-dihydroquinoline-3-carboxamide moiety","volume":"26","author":"Tang","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib146","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejmech.2018.08.066","article-title":"Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 1,8-naphthyridin-2-one moiety","volume":"158","author":"Tang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib147","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1016\/j.bmc.2019.05.007","article-title":"Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors","volume":"27","author":"Nan","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib148","doi-asserted-by":"crossref","first-page":"112241","DOI":"10.1016\/j.ejmech.2020.112241","article-title":"Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions","volume":"193","author":"Nan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib149","doi-asserted-by":"crossref","first-page":"111803","DOI":"10.1016\/j.ejmech.2019.111803","article-title":"Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold","volume":"185","author":"Wang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib150","doi-asserted-by":"crossref","first-page":"112174","DOI":"10.1016\/j.ejmech.2020.112174","article-title":"Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate","volume":"192","author":"Chen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib151","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ejmech.2018.01.061","article-title":"Identification of novel N1-(2-aryl-1, 3-thiazolidin-4-one)-N3-aryl ureas showing potent multi-tyrosine kinase inhibitory activities","volume":"146","author":"Qi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib152","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejmech.2018.11.057","article-title":"Discovery of N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment","volume":"163","author":"Qi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib153","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.bmc.2019.03.049","article-title":"Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2","volume":"27","author":"Qi","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib154","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1021\/jm8006189","article-title":"Design, synthesis, and biological evaluation of potent c-Met inhibitors","volume":"51","author":"D'Angelo","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib155","doi-asserted-by":"crossref","first-page":"115555","DOI":"10.1016\/j.bmc.2020.115555","article-title":"Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2","volume":"28","author":"Xu","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib156","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ejmech.2018.03.049","article-title":"Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: synthesis, SAR study, and biological activity","volume":"150","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib157","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1021\/acs.chemrestox.8b00191","article-title":"Evaluation of deuterium-labeled JNJ38877605: pharmacokinetic, metabolic, and in\u00a0vivo antitumor profiles","volume":"31","author":"Zhan","year":"2018","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2021.113865_bib158","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ijc.28246","article-title":"The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications","volume":"134","author":"Paccez","year":"2014","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ejmech.2021.113865_bib159","doi-asserted-by":"crossref","first-page":"874","DOI":"10.18632\/oncotarget.360","article-title":"Mechanisms of AXL overexpression and function in imatinibresistant chronic myeloid leukemia cells","volume":"2","author":"Dufies","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2021.113865_bib160","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1021\/jm030427r","article-title":"Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N\u2032-{4-(4-quinolyloxy)phenyl}ureas","volume":"48","author":"Kubo","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib161","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-14-1009","article-title":"AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs","volume":"74","author":"Wilson","year":"2014","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib162","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1021\/acs.jmedchem.8b00672","article-title":"Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as novel AXL kinase inhibitors","volume":"61","author":"Szabadkai","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib163","doi-asserted-by":"crossref","first-page":"111867","DOI":"10.1016\/j.ejmech.2019.111867","article-title":"Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker","volume":"186","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib164","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.113865_bib165","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2021.113865_bib166","doi-asserted-by":"crossref","first-page":"8456","DOI":"10.1021\/acs.jmedchem.6b00902","article-title":"Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I \u201cgatekeeper\u201d Mutant of cKIT Kina","volume":"59","author":"Li","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib167","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1021\/acs.jmedchem.9b00280","article-title":"Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)- N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a novel orally available potent inhibitor against broad-spectrum mutants of c-KIT kinase for gastrointestinal stromal tumors","volume":"62","author":"Wu","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib168","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3324\/haematol.2009.017079","article-title":"Pim serine\/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers","volume":"95","author":"Brault","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2021.113865_bib169","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.bmcl.2011.12.130","article-title":"Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors","volume":"22","author":"Pastor","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejmech.2019.02.022","article-title":"Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors","volume":"168","author":"Mart\u00ednez-Gonz\u00e1lez","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib171","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.bbamcr.2011.06.009","article-title":"Thrombin activation of PI3K\/PDK1\/Akt signaling promotes cyclin D1 upregulation and RPE cell proliferation","volume":"1813","author":"Parrales","year":"2011","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib172","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2021.113865_bib173","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.bioorg.2018.09.011","article-title":"Unveiling novel 2-cyclopropyl-3-ethynyl-4-(4-fluorophenyl)quinolines as GPCR ligands via PI3-kinase\/PAR-1 antagonism and platelet aggregation valuations; development of a new class of anticancer drugs with thrombolytic effects","volume":"81","author":"Thangarasu","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib174","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2021.113865_bib175","series-title":"Multiple Outcomes for PI3K\/Akt\/mTOR Pathway Targeting in Non-hodgkin Lymphoma","author":"M\u00fcller","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113865_bib176","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.bioorg.2018.10.064","article-title":"New quinoline\/chalcone hybrids as anti-cancer agents: design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity","volume":"82","author":"Abbas","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib177","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113037","article-title":"Dual pharmacological targeting of the MAP kinase and PI3K\/mTOR pathway in preclinical models of colorectal cancer","volume":"9","author":"Pitts","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2021.113865_bib178","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/leu.2016.83","article-title":"MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia","volume":"30","author":"Cant\u00e9-Barrett","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2021.113865_bib179","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00044-020-02502-x","article-title":"A\u00a0conjugated mTOR\/MEK bifunctional inhibitor as potential polypharmacological anticancer agent: the prototype compound discovery","volume":"29","author":"Tao","year":"2020","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib180","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/jhet.3202","article-title":"Synthesis of substituted quinolinyl ether-based inhibitors of PI3K as potential anticancer agents","volume":"55","author":"Aggile","year":"2018","journal-title":"J.\u00a0Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib181","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrc2964","article-title":"Shared and separate functions of polo-like kinases and aurora kinases in cancer","volume":"10","author":"Lens","year":"2010","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2021.113865_bib182","doi-asserted-by":"crossref","first-page":"115525","DOI":"10.1016\/j.bmc.2020.115525","article-title":"Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA\/B) inhibitors: synthesis, biological evaluation and in silico insights","volume":"28","author":"Al-Sanea","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib183","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1016\/j.bmc.2019.07.016","article-title":"Optimization and biological evaluation of nicotinamide derivatives as Aurora kinase inhibitors","volume":"27","author":"Qi","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib184","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2174\/138955708784567430","article-title":"The development of pro-apoptotic cancer therapeutics","volume":"8","author":"Ziedan","year":"2008","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib185","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3390\/molecules24071274","article-title":"New quinoline-based heterocycles as anticancer agents targeting bcl-2","volume":"24","author":"Hamdy","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.113865_bib186","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc2293","article-title":"Survivin, cancer networks and pathway-directed drug discovery","volume":"8","author":"Altieri","year":"2008","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2021.113865_bib187","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1038\/sj.onc.1208049","article-title":"Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms","volume":"23","author":"Chakravarti","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2021.113865_bib188","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1476-4598-8-43","article-title":"Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers","volume":"8","author":"Cheung","year":"2009","journal-title":"Mol. Canc."},{"key":"10.1016\/j.ejmech.2021.113865_bib189","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejmech.2018.02.045","article-title":"Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors","volume":"149","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib190","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/sj.cdd.4400594","article-title":"Caspase inhibitors","volume":"6","author":"Ekert","year":"1999","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2021.113865_bib191","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ejmech.2018.04.014","article-title":"Novel hydrazide-hydrazone and amide substituted coumarin derivatives: synthesis, cytotoxicity screening, microarray, radiolabeling and in\u00a0vivo pharmacokinetic studies","volume":"151","author":"Nasr","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib192","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.bmcl.2011.12.037","article-title":"Synthesis and DNA cleavage studies of novel quinoline oxime esters","volume":"22","author":"Bindu","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib193","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ardp.200500250","article-title":"C-(2-Chloroquinoline-3-yl)-N-phenyl nitrone: new synthetic antioxidant inhibits proliferation and induces apoptosis of breast carcinoma MCF-7 cells","volume":"339","author":"Ramadan","year":"2006","journal-title":"Arch. Der Pharm. Chem. Life Sci."},{"key":"10.1016\/j.ejmech.2021.113865_bib194","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/15216540152845993","article-title":"Nitric oxide, mitochondria, and cell death","volume":"52","author":"Brown","year":"2001","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ejmech.2021.113865_bib195","article-title":"Novel quinoline derivatives carrying nitrones\/oximes nitric oxide donors: design, synthesis, antiproliferative and caspase-3 activation activities","volume":"352","author":"Abdelbaset","year":"2019","journal-title":"Arch. Der Pharm. Chem. Life Sci."},{"key":"10.1016\/j.ejmech.2021.113865_bib196","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/cancers10050152","article-title":"40 Years of research put p53 in translation","volume":"10","author":"Marcel","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2021.113865_bib197","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ejmech.2018.11.048","article-title":"Design, synthesis, structure-activity relationships and mechanism of action of new quinoline derivatives as potential antitumor agents","volume":"162","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib198","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ejmech.2019.05.061","article-title":"The synthesis and anticancer activity of 2-styrylquinoline derivatives. A p53 independent mechanism of action","volume":"177","author":"Mrozek-Wilczkiewicz","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib199","doi-asserted-by":"crossref","first-page":"41363","DOI":"10.18632\/oncotarget.9133","article-title":"COTI-2, a novel small molecule that is active against multiple human cancer cell lines in\u00a0vitro and in\u00a0vivo","volume":"7","author":"Salim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2021.113865_bib200","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10637-008-9123-6","article-title":"A\u00a0phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas","volume":"26","author":"Attia","year":"2008","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2021.113865_bib201","doi-asserted-by":"crossref","first-page":"35768","DOI":"10.1074\/jbc.M112.396911","article-title":"Mechanistic studies of semicarbazone triapine targeting human ribonucleotide reductase in\u00a0vitro and in mammalian cells: tyrosyl radical quenching not involving reactive oxygen species","volume":"287","author":"Aye","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib202","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejmech.2019.03.027","article-title":"Anticancer activity of the thiosemicarbazones that are based on di-2-pyridine ketone and quinoline moiety","volume":"171","author":"Mrozek-Wilczkiewicz","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib203","doi-asserted-by":"crossref","first-page":"24376","DOI":"10.1039\/C8RA04640A","article-title":"Design, synthesis and pharmacological evaluation of novel 2-chloro-3-(1H-benzo[d]imidazole-2-yl)quinoline derivatives as antitumor agents: in\u00a0vitro and in\u00a0vivo antitumor activity, cell cycle arrest and apoptotic response","volume":"8","author":"Kuang","year":"2018","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2021.113865_bib204","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/febs.13555","article-title":"Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery","volume":"283","author":"Wang","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2021.113865_bib205","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1007\/s11095-012-0828-z","article-title":"An overview of tubulin inhibitors that interact with the colchicine binding site","volume":"29","author":"Lu","year":"2012","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejmech.2021.113865_bib206","first-page":"1829","article-title":"Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature","volume":"57","author":"Dark","year":"1997","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib207","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bioorg.2018.06.003","article-title":"Novel pyrrol-2(3H)-ones and pyridazin-3(2H)-ones carrying quinoline scaffold as anti-proliferative tubulin polymerization inhibitors","volume":"80","author":"Abdelbaset","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib208","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1158\/0008-5472.CAN-07-0127","article-title":"MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps","volume":"67","author":"Kasibhatla","year":"2007","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib209","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ejmech.2017.07.040","article-title":"Design, synthesis and biological evaluation of 4-anilinoquinoline derivatives as novel potent tubulin depolymerization agents","volume":"138","author":"Zhou","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib210","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejmech.2019.02.038","article-title":"N,N-bis-heteroaryl methylamines: potent anti-mitotic and highly cytotoxic agents","volume":"168","author":"Khelifi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib211","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ejmech.2016.11.012","article-title":"Design, synthesis and anticancer properties of IsoCombretaQuinolines as potent tubulin assembly inhibitors","volume":"127","author":"Khelifi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib212","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejmech.2018.11.070","article-title":"Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site","volume":"163","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib213","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0960-894X(98)00162-0","article-title":"Potent antimitotic and cell growth inhibitory properties of substituted chalcones","volume":"8","author":"Ducki","year":"1998","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib214","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.4155\/fmc-2017-0100","article-title":"Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures","volume":"9","author":"Li","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib215","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4155\/fmc-2016-0047","article-title":"Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents, an update (2013-2015)","volume":"8","author":"Patil","year":"2016","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib216","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1021\/acs.jmedchem.8b01755","article-title":"Discovery of novel quinoline-chalcone derivatives as potent antitumor agents with microtubule polymerization inhibitory activity","volume":"62","author":"Li","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib217","doi-asserted-by":"crossref","first-page":"127310","DOI":"10.1016\/j.molstruc.2019.127310","article-title":"Synthesis, structure-activity relationship and molecular docking studies of novel quinoline-chalcone hybrids as potential anticancer agents and tubulin inhibitors","volume":"1202","author":"Mirzaei","year":"2020","journal-title":"J.\u00a0Mol. Struct."},{"key":"10.1016\/j.ejmech.2021.113865_bib218","doi-asserted-by":"crossref","first-page":"103711","DOI":"10.1016\/j.bioorg.2020.103711","article-title":"Design, synthesis and biological evaluation of novel 5,6,7-trimethoxy-N-aryl-2-styrylquinolin-4-amines as potential anticancer agents and tubulin polymerization inhibitors","volume":"98","author":"Mirzaei","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib219","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1080\/14756366.2019.1639696","article-title":"Anticancer sulfonamide hybrids that inhibit bladder cancer cells growth and migration as tubulin polymerisation inhibitors","volume":"34","author":"Liu","year":"2019","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib220","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10637-019-00799-z","article-title":"Anticancer evaluation of a novel dithiocarbamate hybrid as the tubulin polymerization inhibitor","volume":"38","author":"Liu","year":"2020","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2021.113865_bib221","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1016\/j.tetlet.2013.07.115","article-title":"A\u00a0stereoselective route to 6-substituted pyrrolo-1,5-benzoxazepinones and their analogues","volume":"54","author":"Brindisi","year":"2013","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2021.113865_bib222","first-page":"2367","article-title":"Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines","volume":"7","author":"Greene","year":"2016","journal-title":"J.\u00a0Canc."},{"key":"10.1016\/j.ejmech.2021.113865_bib223","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1021\/jm049402y","article-title":"Pyrrolo[1,5]benzoxa(thia)zepines as a new class of potent apoptotic agents. Biological studies and identification of an intracellular location of their drug target","volume":"48","author":"Mc Gee","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib224","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejmech.2018.11.004","article-title":"Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents","volume":"162","author":"Brindisi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib225","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2174\/1871520618666181112121058","article-title":"Hybridized quinoline derivatives as anticancer agents: design, synthesis, biological evaluation and molecular docking","volume":"19","author":"Selim","year":"2018","journal-title":"Anticancer. Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib226","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrm831","article-title":"Cellular roles of DNA topoisomerases: a molecular perspective","volume":"3","author":"Wang","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.113865_bib227","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cb300648v","article-title":"Drugging topoisomerases: lessons and challenges","volume":"8","author":"Pommier","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.113865_bib228","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2021.113865_bib229","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.2174\/092986712799320529","article-title":"Targeting DNA topoisomerase I with non-camptothecin poisons","volume":"19","author":"Beretta","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib230","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1021\/acs.jmedchem.8b01938","article-title":"Discovery and mechanistic study of tailor-made quinoline derivatives as topoisomerase 1 poison with potent anticancer activity","volume":"62","author":"Kundu","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib231","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejmech.2018.02.058","article-title":"Novel topoisomerase I inhibitors. Syntheses and biological evaluation of phosphorus substituted quinoline derivates with antiproliferative activity","volume":"149","author":"Alonso","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib232","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejmech.2017.05.023","article-title":"Thiosemicarbazones and 4-thiazolidinones indole-based derivatives: synthesis, evaluation of antiproliferative activity, cell death mechanisms and topoisomerase inhibition assay","volume":"136","author":"de Oliveira","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib233","doi-asserted-by":"crossref","first-page":"111592","DOI":"10.1016\/j.ejmech.2019.111592","article-title":"Novel 4-quinoline-thiosemicarbazone derivatives: synthesis, antiproliferative activity, in\u00a0vitro and in silico biomacromolecule interaction studies and topoisomerase inhibition","volume":"182","author":"Ribeiro","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib234","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature12751","article-title":"Chromatin proteins and modifications as drug targets","volume":"502","author":"Helin","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113865_bib235","first-page":"1","article-title":"Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies","volume":"8","author":"Jos\u00e9-En\u00e9riz","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.113865_bib236","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-8935-5-3","article-title":"Lysine methyltransferase G9a is not required for DNMT3A\/3B anchoring to methylated nucleosomes and maintenance of DNA methylation in somatic cells","volume":"5","author":"Sharma","year":"2012","journal-title":"Epigenet. Chromatin"},{"key":"10.1016\/j.ejmech.2021.113865_bib237","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1021\/acs.jmedchem.7b01926","article-title":"Discovery of reversible DNA methyltransferase and lysine methyltransferase G9a inhibitors with antitumoral in\u00a0vivo efficacy","volume":"61","author":"Rabal","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib238","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1021\/acs.jmedchem.7b01925","article-title":"Detailed exploration around 4-aminoquinolines chemical space to navigate the lysine methyltransferase G9a and DNA methyltransferase biological spaces","volume":"61","author":"Rabal","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib239","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.biochi.2019.11.006","article-title":"Identification of novel quinoline inhibitor for EHMT2\/G9a through virtual screening","volume":"168","author":"Charles","year":"2020","journal-title":"Biochimie"},{"key":"10.1016\/j.ejmech.2021.113865_bib240","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1021\/jm4012627","article-title":"Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells","volume":"57","author":"Valente","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib241","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13148-019-0663-8","article-title":"Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells","volume":"11","author":"Zwergel","year":"2019","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2021.113865_bib242","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","article-title":"MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L","volume":"20","author":"Bernt","year":"2011","journal-title":"Canc. Cell"},{"key":"10.1016\/j.ejmech.2021.113865_bib243","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/acs.jcim.5b00738","article-title":"Identification of novel disruptor of telomeric silencing 1-like (DOT1L) inhibitors through structure-based virtual screening and biological assays","volume":"56","author":"Chen","year":"2016","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2021.113865_bib244","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bioorg.2018.07.022","article-title":"Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors","volume":"80","author":"Zhang","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib245","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nature11262","article-title":"A\u00a0selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response","volume":"488","author":"Kruidenier","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113865_bib246","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/nm.3716","article-title":"Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma","volume":"20","author":"Hashizume","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2021.113865_bib247","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/cr.2007.83","article-title":"JMJD3 is a histone H3K27 demethylase","volume":"17","author":"Xiang","year":"2007","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib248","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/onc.2010.579","article-title":"The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's Lymphoma","volume":"30","author":"Anderton","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2021.113865_bib249","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nature13605","article-title":"Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia","volume":"514","author":"Ntziachristos","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113865_bib250","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1101\/gad.511109","article-title":"Histone demethylase JMJD3 contributes to epigenetic control of INK4a\/ARF by oncogenic RAS","volume":"23","author":"Barradas","year":"2009","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2021.113865_bib251","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/cmdc.201800198","article-title":"Virtual fragment screening identification of a quinoline-5,8-dicarboxylic acid derivative as a selective JMJD3 inhibitor","volume":"13","author":"Giordano","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113865_bib252","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2174\/1381612043383980","article-title":"A\u00a0review of depsipeptide and other histone deacetylase inhibitors in clinical trials","volume":"10","author":"Piekarz","year":"2004","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2021.113865_bib253","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2021.113865_bib254","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2021.113865_bib255","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acs.jmedchem.7b01404","article-title":"(N-Hydroxycarbonylbenylamino)quinolines as selective histone deacetylase 6 inhibitors suppress growth of multiple myeloma in\u00a0vitro and in\u00a0vivo","volume":"61","author":"Lee","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib256","doi-asserted-by":"crossref","first-page":"115250","DOI":"10.1016\/j.bmc.2019.115250","article-title":"Synthesis and biological evaluation of 2-quinolineacrylamides","volume":"28","author":"Wang","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib257","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/156652306775515501","article-title":"Targeting transcription factors for cancer gene therapy","volume":"6","author":"Libermann","year":"2006","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ejmech.2021.113865_bib258","first-page":"417","article-title":"Transcription factors: an overview","volume":"74","author":"Latchman","year":"1993","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.ejmech.2021.113865_bib259","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1158\/0008-5472.CAN-12-4028","article-title":"Nkx2-8 downregulation promotes angiogenesis and activates NF-\u03baB in esophageal cancer","volume":"73","author":"Lin","year":"2013","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib260","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1074\/jbc.M115.641407","article-title":"Phosphatase and tensin homolog (PTEN) represses colon cancer progression through inhibiting paxillin transcription via PI3K\/AKT\/NF-\u03baB pathway","volume":"290","author":"Zhang","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib261","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/cells7100177","article-title":"Targeting DNA binding for NF-\u03baB as an anticancer approach in hepatocellular carcinoma","volume":"7","author":"Chung","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2021.113865_bib262","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1038\/sj.onc.1207383","article-title":"Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis","volume":"23","author":"Xie","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2021.113865_bib263","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2021.113865_bib264","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1021\/acs.jmedchem.6b01672","article-title":"Nitric oxide donor-based cancer therapy: advances and prospects","volume":"60","author":"Huang","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib265","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1021\/acschembio.5b00945","article-title":"Strategies and approaches of targeting STAT3 for cancer treatment","volume":"11","author":"Furtek","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.113865_bib266","doi-asserted-by":"crossref","first-page":"111885","DOI":"10.1016\/j.ejmech.2019.111885","article-title":"NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth","volume":"186","author":"Kaoud","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib267","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","article-title":"Transcriptional amplification in tumor cells with elevated c-Myc","volume":"151","author":"Lin","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2021.113865_bib268","doi-asserted-by":"crossref","first-page":"18249","DOI":"10.1016\/S0021-9258(17)46837-2","article-title":"Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, in\u00a0vitro","volume":"268","author":"Takimoto","year":"1993","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib269","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2018.12.020","article-title":"Syntheses and evaluation of new Quinoline derivatives for inhibition of hnRNP K in regulating oncogene c-myc transcription","volume":"85","author":"Shu","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib270","doi-asserted-by":"crossref","first-page":"103592","DOI":"10.1016\/j.bioorg.2020.103592","article-title":"Synthesis and biological evaluations of N\u2032-substituted methylene-4-(quinoline-4-amino) benzoylhydrazides as potential anti-hepatoma agents","volume":"96","author":"Li","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib271","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0009-8981(99)00224-7","article-title":"Unraveling the role of proteases in cancer","volume":"291","author":"Koblinski","year":"2000","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejmech.2021.113865_bib272","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3748\/wjg.v11.i9.1251","article-title":"Proteolytic-antiproteolytic balance and its regulation in carcinogenesis","volume":"11","author":"Skrzydlewska","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2021.113865_bib273","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1021\/jm301544x","article-title":"Development of new cathepsin b inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives","volume":"56","author":"Sosi\u010d","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib274","doi-asserted-by":"crossref","first-page":"59136","DOI":"10.18632\/oncotarget.19296","article-title":"Addition of 2-(ethylamino)acetonitrile group to nitroxoline results in significantly improved anti-tumor activity in\u00a0vitro and in\u00a0vivo","volume":"8","author":"Mitrovi\u0107","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2021.113865_bib275","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.bmcl.2018.02.042","article-title":"Cathepsin B inhibitors: further exploration of the nitroxoline core","volume":"28","author":"Sosi\u010d","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib276","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1002\/cmdc.202000402","article-title":"Synthesis of novel nitroxoline analogs with potent cathepsin B exopeptidase inhibitory activity","volume":"15","author":"Van de Walle","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113865_bib277","doi-asserted-by":"crossref","first-page":"a014241","DOI":"10.1101\/cshperspect.a014241","article-title":"MYC activation is a hallmark of cancer initiation and maintenance","volume":"4","author":"Gabay","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejmech.2021.113865_bib278","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1021\/acs.jcim.7b00098","article-title":"Machine-learning-assisted approach for discovering novel inhibitors targeting bromodomain-containing protein 4","volume":"57","author":"Xing","year":"2017","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2021.113865_bib279","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejmech.2018.11.018","article-title":"Rational design of 5-((1H-imidazole-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors","volume":"163","author":"Xing","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib280","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.biochi.2015.09.018","article-title":"The paracaspase MALT1","volume":"122","author":"Hachmann","year":"2016","journal-title":"Biochimie"},{"key":"10.1016\/j.ejmech.2021.113865_bib281","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00018-015-2059-z","article-title":"The paracaspase MALT1: biological function and potential for therapeutic inhibition","volume":"73","author":"Jaworski","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2021.113865_bib282","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.bmcl.2019.05.040","article-title":"Quinoline and thiazolopyridine allosteric inhibitors of MALT1","volume":"29","author":"Scott","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib283","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2021.113865_bib284","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1021\/acs.jmedchem.8b01085","article-title":"Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazole-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a potent, selective, and orally available HSP90 inhibitor","volume":"62","author":"Uno","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib285","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12015-010-9208-4","article-title":"The role of human aldehyde dehydrogenase in normal and cancer stem cells","volume":"7","author":"Ma","year":"2011","journal-title":"Stem Cell Rev. Reports."},{"key":"10.1016\/j.ejmech.2021.113865_bib286","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1021\/acs.jmedchem.8b00270","article-title":"Discovery of orally bioavailable, quinoline-based aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with potent cellular activity","volume":"61","author":"Yang","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib287","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2174\/138955711797247707","article-title":"Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors","volume":"11","author":"Vyas","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib288","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.molmed.2005.07.003","article-title":"Pyrimidine pathways in health and disease","volume":"11","author":"L\u00f6ffler","year":"2005","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2021.113865_bib289","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/jps.2600780204","article-title":"Self-association and solubility behaviors of a novel anticancer agent, brequinar sodium","volume":"78","author":"King","year":"1989","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2021.113865_bib290","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1021\/acs.jmedchem.7b01862","article-title":"Design, synthesis, and biological evaluation of 4-quinoline carboxylic acids as inhibitors of dihydroorotate dehydrogenase","volume":"61","author":"Madak","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib291","first-page":"3579","article-title":"Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma","volume":"26","author":"Zheng","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib292","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.2005.03.170","article-title":"Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer","volume":"23","author":"Bissett","year":"2005","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2021.113865_bib293","doi-asserted-by":"crossref","first-page":"111563","DOI":"10.1016\/j.ejmech.2019.111563","article-title":"Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors","volume":"181","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib294","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1158\/0008-5472.CAN-07-0323","article-title":"NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20S proteasomal degradation leading to stabilization and activation of p53","volume":"67","author":"Gong","year":"2007","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113865_bib295","doi-asserted-by":"crossref","first-page":"111649","DOI":"10.1016\/j.ejmech.2019.111649","article-title":"Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2)","volume":"182","author":"Hussein","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib296","first-page":"1348","article-title":"Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer","volume":"155","author":"Lorente","year":"1996","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.ejmech.2021.113865_bib297","doi-asserted-by":"crossref","first-page":"103171","DOI":"10.1016\/j.bioorg.2019.103171","article-title":"Discovery, synthesis and molecular substantiation of N-(benzo[d]thiazol-2-yl)-2-hydroxyquinoline-4-carboxamides as anticancer agents","volume":"91","author":"Bindu","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib298","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrc1926","article-title":"Tumour microenvironment - TGF\u0392: the molecular Jekyll and Hyde of cancer","volume":"6","author":"Bierie","year":"2006","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2021.113865_bib299","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.ejmech.2021.113865_bib300","doi-asserted-by":"crossref","first-page":"126822","DOI":"10.1016\/j.bmcl.2019.126822","article-title":"Synthesis and evaluation of the HIF-1\u03b1 inhibitory activity of 3(5)-substituted-4-(quinolin-4-yl)- and 4-(2-phenylpyridin-4-yl)pyrazoles as inhibitors of ALK5","volume":"30","author":"Li","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113865_bib301","doi-asserted-by":"crossref","first-page":"64460","DOI":"10.1039\/C6RA09891F","article-title":"Synthesis of quinoline acetohydrazide-hydrazone derivatives evaluated as DNA gyrase inhibitors and potent antimicrobial agents","volume":"6","author":"Sridhar","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2021.113865_bib302","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2021.113865_bib303","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.molstruc.2017.10.075","article-title":"Drug repurposing of novel quinoline acetohydrazide derivatives as potent COX-2 inhibitors and anti-cancer agents","volume":"1154","author":"Manohar","year":"2018","journal-title":"J.\u00a0Mol. Struct."},{"key":"10.1016\/j.ejmech.2021.113865_bib304","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrc.2017.53","article-title":"Targeting autophagy in cancer","volume":"17","author":"Levy","year":"2017","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2021.113865_bib305","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejmech.2019.05.088","article-title":"Design, synthesis and biological evaluation of new quinoline derivatives as potential antitumor agents","volume":"178","author":"Su","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib306","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2016.12.007","article-title":"Proteasome inhibitors in cancer therapy: treatment regimen and peripheral neuropathy as a side effect","volume":"103","author":"Kaplan","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2021.113865_bib307","first-page":"47","article-title":"Resistance to proteasome inhibitors in multiple myeloma","author":"Cottini","year":"2014","journal-title":"Springer, Cham"},{"key":"10.1016\/j.ejmech.2021.113865_bib308","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ejmech.2018.09.037","article-title":"Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines","volume":"158","author":"Hu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113865_bib309","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00280-019-03773-x","article-title":"In\u00a0vitro and in\u00a0vivo anticancer effects of two quinoline\u2013platinum(II) complexes on human osteosarcoma models","volume":"83","author":"Ruiz","year":"2019","journal-title":"Canc. Chemother. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421007145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421007145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:39:45Z","timestamp":1759329585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421007145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":309,"alternative-id":["S0223523421007145"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113865","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent contributions of quinolines to antimalarial and anticancer drug discovery research","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113865"}}